Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noscapine for Refractory NHL or CLL
NCT00183950Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Mar 2000
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of noscapine in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by University of Southern California. Primary endpoint: Tumor Shrinkage. Started Mar 2000; status: terminated.
02
Drugs
noscapine
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00183950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183950.